A prospective and randomized study of concurrent chemoradiotherapy for stage Ⅲ non-small-cell lung cancer

VernacularTitle:Ⅲ期非小细胞肺癌同步放化疗的临床研究
Author: Shuqing WU
Publication Type:Journal Article
Keywords: Carcinoma,non-small-cell lung; Concurrent chemoradiotherapy; Treatment outcome
From: Cancer Research and Clinic 2009;21(6):403-405
CountryChina
Language:Chinese
Abstract: Objective To evaluate the efficacy and toxicity of concurrent chemoradiotherapy for unresectable stage Ⅲ non-small-cell lung cancer. Methods Fifty-two patients with unresectable stage Ⅲ non-small-cell lung cancer were randomized into group A and B. The method of radiotherapy was the same. All patients were irradiated 2.0 Gy/per fraction, five fractions a week, the total radiation dose was 60～ 64 Gy in tumor. Group A received chemotherapy with 45 mg/m2 of paclitaxel on every Monday. Group B received 30 mg/m2 of cisplatin on days 2 to 4 and 23 to 25 and 135 mg/m2 of paclitaxel on days 1 and 22 concomitant with the radiotherapy. Results The CR (complete response) rates were 22 % and 14 % respectively(P<0.05). Local tumor control time of group A was longer than group B(P=0.0493). Survival rate of group A was higher than group B (P=0.0532). The difference between the toxicity was not statistically significant in both groups (P>0.05). Conclusion The efficacy of low-dose every week was more effective than high-dose every three weeks and it's local tumor control time and survival was longer than later.